HC Wainwright Reaffirms “Buy” Rating for Sensei Biotherapeutics (NASDAQ:SNSE)

HC Wainwright reissued their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a report released on Wednesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

Sensei Biotherapeutics Trading Down 3.3 %

SNSE stock opened at $0.51 on Wednesday. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The stock has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.56. The company has a market cap of $12.89 million, a PE ratio of -0.43 and a beta of 0.17.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent reporting period. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.